Most people with moderate or mild hemophilia A who received preventive treatment with Hemlibra (emicizumab) in the HAVEN 6…
Articles by Marisa Wexler, MS
Japan’s Ministry of Health, Labor and Welfare has extended Hemlibra (emicizumab)’s approval to include routine prophylaxis to prevent or lower…
Dosing has begun in a second group of hemophilia B patients enrolled in a Phase 1/2 dose-confirmation trial of…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to efanesoctocog alfa, an experimental replacement therapy…
Katherine High, MD, has received the gold medal from Children’s Hospital of Philadelphia (CHOP) in recognition of her work to…
Roche has extended its partnership with the World Federation of Hemophilia (WFH) to expand access to treatments for…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
Osteoporosis and other bone disorders are more common in hemophilia carriers than in the general population, according to an analysis…
Treatment with the experimental gene therapy Roctavian (valoctocogene roxaparvovec) significantly increased factor VIII levels in men with severe…
The first participant has been dosed in a Phase 1/2 dose-confirmation trial that is testing FLT180a, an experimental gene therapy…